Scinai Immunotherapeutics Ltd. (SCNI) intrinsic value & 10-year financials
Scinai Immunotherapeutics Ltd. (SCNI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue shrank 77.4% a year to $1.3M, with an average return on invested capital of 143.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.75
- Market cap
- $7.0B
- Revenue (FY2025)
- $1.3M
- Revenue growth (7-yr CAGR)
- -77.4%
- ROIC (10-yr avg)
- 143.4%
- Free cash flow (FY2025)
- -$6.1M
SCNI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.3M | -$8.3M | — | -$6.1M | -575.3% | -94.9% |
| FY2024 | $389 | $4.8M | — | -$6.3M | -2220565.6% | 1240.9% |
| FY2023 | $25.6M | -$6.5M | -$0.00 | -$10.0M | 37.9% | 56.5% |
| FY2022 | — | -$5.8M | -$0.00 | -$8.1M | — | 40.0% |
| FY2021 | — | -$8.2M | -$0.00 | -$7.6M | — | 56.3% |
| FY2020 | — | -$1.4M | — | -$24.5M | — | -233.5% |
| FY2017 | — | -$10.0M | — | -$4.2M | — | -61.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Scinai Immunotherapeutics Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Scinai Immunotherapeutics Ltd. has historically struggled to out-earn its cost of capital, averaging just 0.9% ROIC.
Scinai Immunotherapeutics Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Scinai Immunotherapeutics Ltd. is modeled at -77.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.06 per share.